🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to scientists.

An International Health Concern

Gonorrhoea infections are escalating worldwide, with figures suggesting in excess of 82 million infections each year. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the face of growing infection rates, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in recent days for combating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in the same week. This drug, which is also used to treat UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a unique collaborative effort for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to see it through.

“This approval signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Outcomes and Global Access

Based on results published in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This places it at an similar efficacy with the typical regimen, which uses a dual-drug approach. The study involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have shared optimism. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is deemed vital to reduce the burden of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.